Business
Medacta : 2024 Annual Presentation
Medacta : 2024 Annual
About this update from Medacta Group Sa
2024 FULL YEAR RESULTS SUSTAINABLE INNOVATION, WORLD-CLASS SURGEON EDUCATION, AND AN UNWAVERING COMMITMENT TO IMPROVING PATIENT OUTCOMES 25 March 2025 FRANCESCO SICCARDI Chief Executive Officer Highlights - 2024 Full Year Results Notes * constant currency ** Alternative Performance Measures: This presentation contains certain financial measures of historical performance that are not defined or specified by IFRS, suc h as "such as "constant currency", "EBITDA", "Adjusted EBITDA" or "CORE EBITDA", "Adjusted and Normalized EBITDA", "Free Cash Fl ow", "Adjusted Free Cash Flow", "Adjusted and Normalized Free Cash Flow", "Net Debt" and "Leverage". Reconciliation of these measures as well as "CORE" financial measures is provided in the "Alternative Performance Measures" ( APM) section of the 2024 Annual Report. These Alternative Performance Measures (APM) should be regarded as complementary information to, and not as a substitute for the IFRS beginning performance measures. For definitions of APM, together with reconciliations to the most directly reconcilable IFRS line items, please refer section headed "Alternative Performance Measures" of the 2024 Annual Report. The 2024 Annual Report is available at https://www.medacta.com/EN/financial-reports-and-presentations . Considerable above market revenue growth Group revenue CAGR* (2020-2024): EURm 600 500 400 300 200 100 0 2020 * In constant currency • 2024 revenue growth* of 16.2% yoy • Revenue CAGR* (2020-2024) of 18.1% • Considerable above revenue growth as result of market • Out-of-the-box thinking innovations to improve patient outcome and healthcare sustainability • Education and personalised training of surgeons 2021 2022 2023 2024 • Further expansion of sales reps and team Outstanding growth across all geographies 15.1 40.0 510.8 EURm 16.5% 25.4 16.5% 14.5% 2.3 22.5% Growth rate in constant currency FY 2023 EMEA NA APAC LATAM FY 2024 in cc* • EMEA and NA: outstanding growth rate* of 16.5% • APAC: excellent growth rate* in major markets • LATAM: growth rate* in the low twenties * in constant currency 593.6 Abbreviations: EMEA: Europe, Middle East and Africa; NA: North America; APAC: Asia Pacific; LATAM: Latin America 590.6 -3.0 FX FY 2024 FY 2024 geographic revenue distribution LATAM EUR 12.4m, 2% Clear market outperformance across all business lines 14.1 43.4 510.8 EURm 19.0 8.3% 21.9% 38.8% 6.2 13.4% Growth rate in constant currency 593.6 590.6 -3.0 FY 2024 revenue distribution by business line * in constant currency ** Extremities includes Shoulder and Sportsmed Solid growth in Hip Hip Revenue CAGR* (2020-2024): 12.8% EURm 250 200 150 100 50 0 2020 Hip 2021 2022 2023 2024 • Growth mainly attributable to Medacta's Anterior Minimally Invasive Surgery (AMIS) platform • > 2 times market outperformance 2024E** yoy Notable expansion in Knee Knee Revenue CAGR* (2020-2024): 22.1% 250 200 EURm 150 100 50 0 2020 2021 2022 2023 2024 Knee • Outstanding performance due to Medacta's personalised Kinematic Alignment platform MyKA and GMK SpheriKA • Robust growth across all geographic regions • > 3 times market outperformance 2024E** yoy Outstanding growth in Spine Spine Revenue CAGR* (2020-2024): 17.1% 60 EURm 50 40 30 20 10 0 2020 Spine 2021 2022 2023 2024 • Solid revenue acceleration strongly supported Medacta's technologies, particularly by NextAR Spine • Particularly strong performance in EMEA • > 3 times market outperformance 2024E** yoy by Attention : This is an excerpt of the original content. To continue reading it, access the original document here .